We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

47 hedge funds and large institutions have $27.9M invested in Tempest Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

11% less capital invested

Capital invested by funds: $31.3M → $27.9M (-$3.41M)

13% less funds holding

Funds holding: 54 → 47 (-7)

20% less call options, than puts

Call options by funds: $4K | Put options by funds: $5K

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
47
Holders Change
-7
Holders Change %
-12.96%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
11
Closed
11
Calls
$4K
Puts
$5K
Net Calls
-$1K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$1.18M
2
GC
GMT Capital
Georgia
+$1.17M
3
BC
Broadfin Capital
New York
+$402K
4
DMK
David M. Knott
+$180K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$120K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.96M
2
Legal & General Group
Legal & General Group
United Kingdom
-$713K
3
ECM
Element Capital Management
New York
-$188K
4
PP
Paloma Partners
Connecticut
-$180K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$176K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$5.63M -$1.96M -459 -25%
EC
2
EcoR1 Capital
California
$4.99M – – –
Jennison Associates
3
Jennison Associates
New York
$3.11M -$4.28K -1 -0.1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.17M +$29.9K +7 +1%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$1.82M – – –
ACA
6
Avoro Capital Advisors
New York
$1.59M +$1.18M +277 +259%
GC
7
GMT Capital
Georgia
$1.14M +$1.17M +274 New
Franklin Resources
8
Franklin Resources
California
$903K – – –
SM
9
Sabby Management
Florida
$781K +$59.8K +14 +8%
BC
10
Broadfin Capital
New York
$781K +$402K +94 +100%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$707K +$120K +28 +20%
BlackRock
12
BlackRock
New York
$650K -$12.8K -3 -2%
Millennium Management
13
Millennium Management
New York
$572K -$21.4K -5 -3%
TS
14
Third Security
Virginia
$530K – – –
BCM
15
BBT Capital Management
Texas
$360K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$322K – – –
Wells Fargo
17
Wells Fargo
California
$259K +$25.6K +6 +11%
AIC
18
AWM Investment Company
New York
$213K – – –
DMK
19
David M. Knott
$196K +$180K +42 +840%
NCMW
20
Northern Capital Management (Wisconsin)
Wisconsin
$129K – – –
ERSOT
21
Employees Retirement System of Texas
Texas
$127K – – –
Northern Trust
22
Northern Trust
Illinois
$103K -$17.1K -4 -14%
ARTA
23
A.R.T. Advisors
New York
$96K +$21.4K +5 +28%
VF
24
Virtu Financial
New York
$92K +$94K +22 New
HCM
25
Howland Capital Management
Massachusetts
$89K -$81.2K -19 -48%
1
2 3

TPST Hedge Fund Activity: Q3 2017 in Review

47 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2017, worth a combined $27.9M — down 11% from $31.3M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of TPST and 5 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $1.18M. The largest seller was Fidelity Investments, cutting an estimated $1.96M.

  • 47 institutional investors held Tempest Therapeutics (TPST) as of Q3 2017, down from 54 in Q2 2017.
  • Funds reported $27.9M of Tempest Therapeutics stock for Q3 2017, down 11% quarter-over-quarter.
  • 5 funds opened new Tempest Therapeutics positions in Q3 2017 and 11 closed out, a net change of -6 holders.
  • The largest Tempest Therapeutics buyer in Q3 2017 was Avoro Capital Advisors, an estimated $1.18M added.
  • The largest Tempest Therapeutics seller in Q3 2017 was Fidelity Investments, an estimated $1.96M sold.

Based on aggregated 13F filings for Q3 2017.